Meningococcal Vaccine Could Protect Against 91% of Targeted Bacterial Strains
News Nov 23, 2017 | Original story from the American Society for Microbiology
Up to 91 percent of bacterial strains causing a common type of invasive serogroup B meningococcal disease in children and young adults express at least one of the antigens contained in a four-component vaccine called MenB-4C (Bexsero), according to laboratory studies conducted by investigators at the federal Centers for Disease Control and Prevention (CDC) and at GlaxoSmithKline, manufacturers of the vaccine. The work was published this week in mSphere, an open access journal from the American Society for Microbiology.
Researchers used a laboratory test called the Meningococcal Antigen Typing System (MATS) to study the coverage potential of the MenB-4C vaccine, which was approved by the Food and Drug Administration in January 2015 for use in individuals ages 10-25 years. The vaccine contains 4 antigens to prevent invasive meningococcal disease caused by the serogroup B form of the bacteria Neisseria meningitidis: factor H binding protein (fHBP), Neisserial heparin binding protein (NHBA), Neisserial adhesin A (NadA) and PorA-containing outer membrane vesicles. These antigens are found on the bacteria, and vaccination with them helps protect an individual from infection by the bacteria that carry the antigens, contingent on their immune response to the vaccine. In the United States in 2015, serogroup B strains of the bacteria caused approximately 40 percent of invasive meningococcal disease in all age groups, including adolescents, and over 60 percent of cases in infants aged less than one year.
Researchers tested 442 N. meningitidis serogroup B bacteria collected by CDC from 2000 to 2008. The MATS test showed that 91 percent of these US bacterial strains express antigens similar to those contained in the MenB-4C vaccine, with an estimated coverage ranging from 88 percent to 97 percent each year.
More than half of the covered strains could be targeted by two or more antigens in the vaccine, the investigators found. MATS data indicated that NHBA was expressed by 83 percent of the strains, fHBP was expressed by 53 percent of the strains, and NadA was expressed by 2.5 percent of the strains.
“We are very pleased to see that it looks like the vaccine has the potential to cover most of the strains of meningococcal Group B bacteria currently circulating in the U.S.,” said lead study author Gowrisankar Rajam, Ph.D., health scientist at CDC. “However, we need to continue our analysis to assess the coverage of currently circulating strains in the U.S. We are confident the MATS technique will be very useful at detecting any changes in bacterial expression of these antigens.”
Neisseria meningitidis is a leading cause of bacterial meningitis in children and young adults, resulting in significant morbidity and mortality worldwide. Meningococcal disease is a life-threatening illness that can infect the bloodstream and the lining that surrounds the brain and spinal cord. The bacteria can be transmitted from person to person through close or prolonged contact with respiratory or throat secretions, such as by coughing, kissing or living in close quarters.
Another vaccine against serogroup B meningococcal disease, called Trumenba, was approved by the FDA in October 2014. Previous vaccines were available to protect against meningococcal disease caused by N. meningitidis serogroups A, C, Y and W but not against serogroup B.
Funding, material and support for the study was provided by GlaxoSmithKline Biologicals SA, manufacturer of the Bexsero meningococcal vaccine. Some of the study co-authors are employed by the company, which was involved in analysis and interpretation of the data and which was provided the opportunity to review a preliminary manuscript for accuracy.
This article has been republished from materials provided by The American Society for Microbiology. Note: material may have been edited for length and content. For further information, please contact the cited source.
Lonza, Akouos and MEE Announce Strategic Gene Therapy License Agreements on Hearing and Balance DisordersNews
Lonza and Massachusetts Eye and Ear (MEE) grant Akouos exclusive licenses to proprietary ancestral AAV (Anc-AAV) vectors for all hearing and balance disorders.READ MORE